Member Info for NFTs

Page 66 resolution number 8 that you all approved.

https://nuformix.com/app/uploads/2022/07/2022-07-22-Nuformix-PLC-YE-31.03.22-v4-FINAL.pdf

September is next AGM

Problem with listing on main market as per the annual shareholder AGM you limit it to 10% so 35 x 2 equals 70 mil approx 10%

I’d expect the placeholder was not willing to buy without the cherry of the warrants making the raise considerably smaller.
So therefore like Lanstead they need approvals for more.
Guess it’s all they needed for moment.

21,000 views in three hours tells a story that it’s bigger than just a few PI’s

Totally agree the term ablation is the meaning of almost near removal of fibrosis material from the lungs. In effect a cure!!
Anyone who know fibrosis knows that most patients die within 3 years but this may prolong life for significantly longer periods and potential to reduce side effects

Yes

I have to say this reads very well for showing the value that NXP002 holds. IPF is particularly difficult area with desperate need for fast to market affordable therapies and NXP002 is exactly that. Perhaps Kissei maybe interested again ;)

Remember the ERS conference recommended this direction and obviously highly liked the direction on SOC for NXP002
This next data if good is a very exciting value inflection point for Nuformix. Those that have patiently waited will see a decent return. We needlessly dropped from 2p after the stupidity of Riddell but now one hopes we can recover on that subject to data which should be soon imo.

Not tranilast but one the SOC drugs NXP002 will improve effects is found as below. Just shows how drugs have often some many other potential unknown benefits

“She recently led a study showing that pirfenidone, a drug used to treat lung fibrosis (where a stiffening of the lung tissue makes it difficult to breathe) can more than double the number of eggs produced by ageing ovaries.

In experiments on 12-month-old mice (equivalent to 35 years in humans), Professor Robker found ovaries become stiffer with age (they had more fibrosis). But when mice were given pirfenidone, it softened the ovaries, making them produce more eggs than untreated mice, the journal Science Advances reported last year”

https://www.dailymail.co.uk/health/article-11882533/The-promising-new-treatments-help-budding-mothers-conceive.html

It’s been a very difficult period but if they can deliver positive data on NXP002 as a successful SOC treatment in diseased lung tissue up there in Newcastle then this definitely changes the direction here.

Best UK shares to buy in April 2023
Rolls-Royce, Scottish Mortgage, and Avacta could constitute three of the best UK shares to buy next month.

If Science Day was considered None Material data for the Pre RNS then I look forward to an RNS that is material:)-
IMO it’s probably not very far down the road. I’d expect a few big hitters imo.

What Pratt knows the end result of an auction before the auction has been held!

That’s why you have expected valuation guide price.

So Rah is saying a guide price if this goes to auction.

What bit do you fail to understand in that process.

Do you think every share on the market is valued now at actual sale price?

Or do you think that’s why we buy into the market!!

Imagine if you were buying let’s just say something obvious as in lump of gold which you knew was 100% 24 carat gold tested and marked with guaranteed weight currently say 1kg but they were adding more and expected that to probably double if not quadruple from there. Yet you were buying it at the set price for 1kg with everything else just being a bonus for coming in early and guaranteeing the money upfront which they needed because let’s say they had other parts of the mine that needs funds.

So your upside for getting that gold at a commercial rate with added bonus of a lot more coming for whatever reason etc, How do you lose?

Any pharmaceutical here will know that already AVA6000 is already multiples better than current Dox. Doxyrubicine is Doxyrubicine regardless of how it’s delivered so it will do what it does which is kill cells. So the industry knows it has a game changer of multiples here whether that be x2 or x50 etc we are not fully informed yet. But it’s certainly enough to get all those inside jumping about excited and flying about to stick in their bit about it.

So what does that mean. Well it means that whoever buys this is going to get the market for Dox for many years with huge upside in potential.

This is just AVA6000 alone which is now worth so many more multiples of current MCAP as we speak alone.
Add the Precision tech platform and other targets incoming along with Affirmers and Diagnostics the MCAP is a joke and any buyer knows the current MCAP is completely irrelevant to actual sale.

Going to be good 2023 ;)

Absolutely

Dr Krishnan Komanduri was brought onto the advisory board for many reasons one being for commercialisation. He will have been the voice to Dr Tap imo and between them all that need to know will hear it from them. That will be all that is required for a major imo to come and buyout the lot. One thing you don’t do is give the game away that you are not going ahead with your own plan as this drives significant bargaining power when TO offers come in.
The enormity of this now is so huge it’s very hard to gauge what a realistic offer is. It sounds ridiculous but 20 billion seems too cheap even at this stage!

I think Dr Tap the leading voice of soft tumour sarcoma, who came over to the UK specially to talk on AVA6000 target market, who explained in fascinating in depth the huge market that Dox is hitting and what an improved version of Dox would do to that market in such that it becomes that market. Then you know he talks to all the majors of the world but most importantly to the big bucks in America knowing to well what AVACTA are sitting on and how commercially and scientifically powerful it is to hold this tech and this drug alone!

I’m sure that the market is just going to go to sleep and not bother hey! I mean why invest in something that is basically going to be the dominant player. Surely!!
I think this has significantly opened the doors to all who need to know.

From what I understand some have been looking in for awhile. Today was obviously to captcha and diversify to a wider market and to affirm officially what they have.
There are some sizeable consistent buyers and sellers at current. No II needs to inform us till 3% and above and if they are from outside the UK I believe it’s 5%.
So may already have some floating just under these levels tactically but perhaps will now get a move on further up.
These companies generally want to be held by II’s not PI’s. This is going to happen.

“We know the "data are unequivocal". We know "that doxorubicin is being released in the tumour tissue and at significant levels, therapeutically relevant levels".
It’s also been explained by some very knowledgeable people and Paul Hills discusses it with AS.
Today efficacy is being answered to standard dose.

Just encase you are not sure what efficacy is meaning then “the ability to produce a desired or intended result.”

It works so you need to find a new job now as you’re agenda is pointless here lol like a spoilt child that cannot stop for attention seeking issues?

It’s already been stated that Dox in standard form is rapid and very destructive in the blood stream as it attacks all organs and falls away within mins where as AVA6000 delivery of Dox stays circulating in the blood hunting it’s fap target for hours delivering a nice direct constant dosage of Dox to the FAP targets.
You really are hunting desperately for nothing.
Agenda etc yawn

https://avacta.com/therapeutics/

All been discussed then no need to worry hey?

How many of these small caps right now have people spouting this same nonsense that they have revenue and could do it via a loan?

These businesses don’t do loans at this stage as the risk to leg lenders is high in trying to recover the debt against intangible assets that are none material in reality as who wants some old packaging and pc etc?
The company is running late and profitability if ever achieved will be late.
They are on this market here to raise cash. You will get UK sales started against many other players over this side of the globe which means they will probably not do too well here but helps them show company for raising capital on next round.

Look about at other small caps and look at how bad the conditions are for raising. If company needs cash this year or next then they are going to hurt holders.

Simple as that. My opinion here is stay clear this has much further to play out down. Sorry but my opinion on open discussion board.

You said all discussed etc so no need to worry then if you are so confident. SP tells a different story and the books.

As to some your pointless questions
WH Ireland Capital Markets Is their joint broker as they are on Main market so won’t be a Nomad as that’s AIM but makes no difference when it comes to raising cash. They all love to dilute.

How is the Strategic Advisor board getting on here? Don’t hear much these days?

The whole point of a New Zealand business to come to the UK Main market is to raise cash easier to fund his 10 year and counting dream that is not growing fast enough to make money!

It’s about money here that’s why we invest. Not to pay directors comfy dreams and ambitions etc.

As a I said early three years too late, Covid has cost them and now inflation will make profit very difficult here.

They need cash to operate and stay afloat. Should raised double last time now it will be a penny probably